Juq 395 Jun 2026

from GLP toxicology:

| Year | Milestone | Key Players | |------|-----------|-------------| | | High‑throughput screen of a 150 k compound library for inhibitors of the MurA enzyme (first step of peptidoglycan synthesis). | Dr. Lena Hoffmann, University of Munich (U‑M); JuqBio’s discovery team | | 2020 | Hit validation: compound #395 showed > 95 % inhibition of MurA in vitro with low cytotoxicity. | JuqBio R&D | | 2021 | Lead optimization: structural analogues synthesized, yielding Juq‑395 (C₁₈H₂₁N₅O₃·HCl). Improved potency (IC₅₀ = 12 nM) and pharmacokinetics. | JuqBio medicinal chemistry group | | 2022 | Patent granted (US 11,473,021 B2). First in‑vivo efficacy demonstrated in a murine thigh infection model against Staphylococcus aureus (including MRSA). | JuqBio pre‑clinical team | | 2023 | IND‑enabling studies completed; GLP toxicology showed no observable adverse effect level (NOAEL) at 100 mg kg⁻¹ day⁻¹ in rats. | CRO contract (Charles River Labs) | | 2024 | Phase I clinical trial (single‑ascending dose) initiated in healthy volunteers (N = 48). Primary safety endpoints met; pharmacokinetic profile favorable (t₁/₂ ≈ 8 h, oral bioavailability ≈ 62 %). | Clinical research unit, Boston, MA | juq 395